Go To Global Site
Welcome to UCB in the United States

Nov

17

Michele’s Story: Living with Tonic-Clonic Seizures

Michele has lived with tonic-clonic seizures since the age of 28 when she experienced her first seizure while swimming in a pool. This Epilepsy Awareness Month, read about her journey to seizure freedom. 

Nov

17

UCB’s VIMPAT® (lacosamide) CV now approved by FDA for primary generalized tonic-clonic seizures and expanded pediatric use for people living with epilepsy

Nov

12

UCB strengthens its gene therapy activities with additional pipeline programs, capabilities and platforms

Nov

11

Hiring Our Heroes: UCB’s Commitment to Veterans in the Workplace

This Veterans Day, UCB is proud to highlight three of our veterans as they share their transition from the military to the civilian workforce, and what it means to be a veteran at UCB.

Nov

10

UCB BEING: Bridging the Gaps for Black Employees

Read about UCB's BEING (Black Employee Interconnecting Network Group) - a new employee resource group founded to create and sustain an environment within UCB that will support recruitment, retention, engagement and professional development, and advancement for Black employees. 

Nov

05

UCB Showcases Key Rheumatology Data at American College of Rheumatology Convergence 2020

Nov

04

Recognizing Non-Radiographic Axial Spondyloarthritis Patients

As we join the rheumatology community at ACR Convergence 2020, Head of U.S. Medical Immunology, Dr. Jeff Stark, shares the importance of a new diagnostic code for nr-axSpA in helping to improve the patient journey and to lead to more innovation. Read more.

Oct

31

Bimekizumab Phase 3 Data Shows Superior Skin Clearance Over Humira® in Moderate-to-Severe Psoriasis Patients

Oct

29

Looking to The Future: How UCB is Supporting Dermatology Patients Now and Tomorrow

Read more from UCB's Head of U.S. Immunology, Camille Lee, who shares how UCB is supporting dermatology patients now throughout the pandemic and in the future. 

Oct

29

UCB Presents Nine Abstracts at EADV 2020, Showcasing Ongoing Commitment to Dermatology